Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma

Journal of Virology

Volumn 86, Issue 9, 2012, Pages 5014-5025

  Sajadi, Mohammad M ^a   Lewis, George K ^a   Seaman, Michael S ^b   Guan, Yongjun ^a   Redfield, Robert R ^a   DeVico, Anthony L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; MONOMER; NEUTRALIZING ANTIBODY;

ADULT; AFFINITY CHROMATOGRAPHY; ANTIBODY BLOOD LEVEL; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; FRACTIONATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGLOBULIN BLOOD LEVEL; ISOELECTRIC FOCUSING; MALE; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; CD4 LYMPHOCYTE COUNT; CROSS REACTIONS; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN VARIABLE REGION; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84861307180     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06547-11     Document Type: Article

References (64)

1. Amadori A, et al. 1990. IgG oligoclonal bands in sera of HIV-1 infected patients are mainly directed against HIV-1 determinants. AIDS Res. Hum. Retroviruses 6:581-586.
2. Biselli R, et al. 1996. Anti-V3 loop spectrotype in HIV-infected individuals during zidovudine therapy. Infection 24:227-233.
3. Bukasa KS, et al. 1988. Anti-HIV antibodies in the CSF of AIDS patients: a serological and immunoblotting study. J. Neurol. Neurosurg. Psych. 51:1063-1068.
4. Dale G, Latner AL, Muckle TJ. 1970. The investigation of myelomatosis by gel isoelectric focusing followed by electrophoresis. J. Clin. Pathol. 23:35-38.
5. D'Amelio R, et al. 1992. Spectrotype of anti-gp120 antibodies remains stable during the course of HIV disease. J. Acquir. Immune Defic. Syndr. 5:930-935.
6. Decker JM, et al. 2005. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 201:1407-1419.
7. del Bono V, et al. 1998. Isoelectric focusing and reverse blotting as a diagnostic tool in pediatric HIV infection. J. Clin. Virol. 11:203-210.
8. Dey AK, David KB, Klasse PJ, Moore JP. 2007. Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. Virology 360:199-208.
9. Dhillon AK, et al. 2007. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 81:6548-6562.
10. Drouet E, et al. 1999. Oligo-monoclonal immunoglobulins frequently develop during concurrent cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections in patients after renal transplantation. Clin. Exp. Immunol. 118:465-472.
11. Feutren G, de The G, Bach JF. 1992. Epstein-Barr virus serology and isoelectrofocusing pattern of serum immunoglobulins in cyclosporin or placebo-treated type I diabetics. J. Autoimmun. 5:161-172.
12. Fouts TR, et al. 2000. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J. Virol. 74:11427-11436.
13. Freedman MH. 1972. The use of preparative liquid isoelectric focusing for the further purification of rabbit antihapten antibodies. J. Immunol. Methods 1:177-198.
14. Gandhi S, et al. 2012. Elucidation of degradants in acidic peak of cation exchange chromatography in an IgG1 monoclonal antibody formed on long-term storage in a liquid formulation. Pharm. Res. 29:209-224.
15. Gea S, et al. 1993. Chagas' disease cardioneuropathy: association of anti-Trypanosoma cruzi and anti-sciatic nerve antibodies. Am. J. Trop. Med. Hyg. 49:581-588.
16. Gibas CJ, Subramaniam S, McCammon JA, Braden BC, Poljak RJ. 1997. pH dependence of antibody/lysozyme complexation. Biochemistry 36:15599-15614.
17. Grimaldi LM, et al. 1988. HTLV-I-associated myelopathy: oligoclonal immunoglobulin G bands contain anti-HTLV-I p24 antibody. Ann. Neurol. 24:727-731.
18. Guan Y, et al. 2009. Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 106:3952-3957.
19. Imanishi T, Hurme M, Sarvas H, Makela O. 1975. Expression of a mouse Ig V gene in antibodies of three immunoglobulin classes. Eur. J. Immunol. 5:198-202.
20. Insel RA, Adderson EE, Carroll WL. 1992. The repertoire of human antibody to the Haemophilus influenzae type b capsular polysaccharide. Int. Rev. Immunol. 9:25-43.
21. Johnson GC, Adams DS, McGuire TC. 1983. Pronounced production of polyclonal immunoglobulin G1 in the synovial fluid of goats with caprine arthritis-encephalitis virus infection. Infect. Immun. 41:805-815.
22. Kaiser R, et al. 1989. Intrathecal synthesis of virus-specific oligoclonal antibodies in patients with enterovirus infection of the central nervous system. J. Neurol. 236:395-399.
23. Lagenaur LA, Villarroel VA, Bundoc V, Dey B, Berger EA. 2010. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates. Retrovirology 7:11.
24. Lehermayr C, Mahler HC, Mader K, Fischer S. 2011. Assessment of net charge and protein-protein interactions of different monoclonal antibodies. J. Pharm. Sci. 100:2551-2562.
25. Lewis GK, et al. 2011. Identification and characterization of an immunogenic hybrid epitope formed by both HIV gp120 and human CD4 proteins. J. Virol. 85:13097-13104.
26. Li M, et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125.
27. Li Y, et al. 2011. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J. Virol. 85:8954-8967.
28. Li Y, et al. 2009. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J. Virol. 83:1045-1059.
29. Moore JP, Sodroski J. 1996. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70:1863-1872.
30. Mortimer GE, Widdowson JP. 1979. Predominance of immunoglobulin G sub-class 3 among the complement-fixing antibodies to streptococcal M-associated protein. Clin. Exp. Immunol. 37:247-258.
31. Moulard M, et al. 2000. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 74:1948-1960.
32. Mouquet H, et al. 2011. Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PLoS One 6:e24078.
33. Muller S, et al. 1993. B-cell abnormalities in AIDS: stable and clonallyrestricted antibody response in HIV-1 infection. Scand. J. Immunol. 38:327-334.
34. Pancera M, et al. 2010. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 84:8098-8110.
35. Perlmutter RM, Davie JM. 1977. Characterization of molecular heterogeneity and multispecificity in homologous idiotypic antisera. J. Immunol. 118:769-774.
36. Prin C, Bene MC, Gobert B, Montagne P, Faure GC. 1995. Isoelectric restriction of human immunoglobulin isotypes. Biochim. Biophys. Acta 1243:287-289.
37. Roos RP, Nalefski EA, Nitayaphan S, Variakojis R, Singh KK. 1987. An isoelectric focusing overlay study of the humoral immune response in Theiler's virus demyelinating disease. J. Neuroimmunol. 13:305-314.
38. Sajadi MM, et al. 2011. Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. J. Acquir. Immune Defic. Syndr. 57:9-15.
39. Salazar-Grueso EF, et al. 1989. Isoelectric focusing studies of serum and cerebrospinal fluid in patients with antecedent poliomyelitis. Ann. Neurol. 26:709-713.
40. Saphire EO, et al. 2001. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293:1155-1159.
41. Sather DN, et al. 2009. Factors associated with the development of crossreactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
42. Sather DN, Stamatatos L. 2010. Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. Vaccine 28(Suppl 2):B8-B12.
43. Scheid JF, et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636-640.
44. Sela M, Mozes E. 1966. Dependence of the chemical nature of antibodies on the net electrical charge of antigens. Proc. Natl. Acad. Sci. U. S. A. 55:445-452.
45. Seppala IJ, Larinkari U, Rasanen T, Valtonen VV. 1981. Occurrence and specificity of antibodies against group-specific polysaccharides in betahemolytic streptococcal infections. Acta Pathol. Microbiol. Scand. B 89:323-334.
46. Shackelford PG, et al. 1987. Subclass distribution of human antibodies to Haemophilus influenzae type b capsular polysaccharide. J. Immunol. 138:587-592.
47. Sinclair D, Galloway E, McKenzie S, Follett EA, Wallace L. 1989. Oligoclonal immunoglobulins in HIV infection. Clin. Chem. 35:1669-1671.
48. Slade HB, Pica RV, Pahwa SG. 1989. Detection of HIV-specific antibodies in infancy by isoelectric focusing and affinity immunoblotting. J. Infect. Dis. 160:126-130.
49. Teplyakov A, et al. 2009. Epitope mapping of anti-interleukin-13 neutralizing antibody CNTO607. J. Mol. Biol. 389:115-123.
50. Ulanova M, Hahn-Zoric M, Lau YL, Lucas A, Hanson LA. 1996. Expression of Haemophilus influenzae type b idiotype 1 on naturally acquired antibodies. Clin. Exp. Immunol. 105:422-428.
51. Ulanova M, et al. 1997. The clonal antibody response to Pseudomonas aeruginosa heat shock protein is highly diverse in cystic fibrosis patients. APMIS 105:449-456.
52. Walker LM, et al. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470.
53. Walker LM, et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
54. Walker LM, et al. 2010. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6:e1001028.
55. Wassall DA, Sinclair IJ. 1985. The serum antibody response of infected rats, rabbits, lambs and calves to Fasciola hepatica adult antigen fractions separated by preparative flatbed iso-electrofocusing. Parasite Immunol. 7:359-366.
56. Wenisch E, et al. 1989. Isolation of human monoclonal antibody isoproteins by preparative isoelectric focusing in immobilized pH gradients. J. Biochem. Biophys. Methods 18:309-322.
57. Williamson AR. 1971. Antibody isoelectric spectra. Analysis of the heterogeneity of antibody molecules in serum by isoelectric focusing in gel and specific detection with hapten. Eur. J. Immunol. 1:390-394.
58. Wisnewski A, Cavacini L, Posner M. 1996. Human antibody variable region gene usage in HIV-1 infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 11:31-38.
59. Wrammert J, et al. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453:667-671.
60. Wu L, et al. 1996. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384:179-183.
61. Wu SJ, et al. 2010. Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng. Des. Sel. 23:643-651.
62. Wu X, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861.
63. Wyatt R, et al. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:5723-5733.
64. Xiang SH, et al. 2003. Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. Virology 315:124-134.